Management of paraneoplastic membranous nephropathy (MN) is directed toward the underlying malignancy. and prescriptions of immune checkpoint inhibitors (ICIs) are skyrocketing in the field of oncology. However. this drug category is usually discouraged for patients with autoimmune disorders (AIDs) because it might trigger immune-related adverse events (irAEs) in the form of flare-ups... https://www.hacklinkci.com/